These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 22759480)

  • 1. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
    Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
    Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
    Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
    Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
    Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
    Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
    Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
    Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
    Msaouel P; Zurita AJ; Huang S; Jonasch E; Tannir NM
    Oncotarget; 2017 Jun; 8(26):42149-42158. PubMed ID: 28178674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney cancer: prognostic and predictive biomarkers for RCC emerge.
    Razzak M
    Nat Rev Urol; 2012 Aug; 9(8):412. PubMed ID: 22824777
    [No Abstract]   [Full Text] [Related]  

  • 14. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in personalised treatment of renal-cell carcinoma.
    Shariat SF; Xylinas E
    Lancet Oncol; 2012 Aug; 13(8):751-2. PubMed ID: 22759479
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.
    Kok VC; Kuo JT
    BMC Urol; 2016 Jul; 16(1):34. PubMed ID: 27377922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
    Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
    J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.